Focused On-demand Library for tRNA (adenine(58)-N(1))-methyltransferase catalytic subunit TRMT61A

Details

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

PARTNER
Receptor.AI
 
UPACC
Q96FX7

UPID:
TRM61_HUMAN

ALTERNATIVE NAMES:
mRNA methyladenosine-N(1)-methyltransferase catalytic subunit TRMT61A; tRNA(m1A58)-methyltransferase subunit TRMT61A

ALTERNATIVE UPACC:
Q96FX7; A6NN78; Q8N7Q9

BACKGROUND:
TRMT61A, functioning as the catalytic subunit of tRNA (adenine-N(1)-)-methyltransferase, is essential for N(1)-methyladenine formation in initiator methionyl-tRNA and a select group of mRNAs. This methylation is critical for the proper functioning of RNA molecules, influencing their stability and role in protein synthesis. The enzyme, also known as mRNA methyladenosine-N(1)-methyltransferase catalytic subunit TRMT61A, highlights the intricate regulation of RNA modifications and their impact on cellular processes.

THERAPEUTIC SIGNIFICANCE:
Exploring the function of TRMT61A offers a pathway to novel therapeutic avenues. As a central player in RNA modification, targeting TRMT61A could provide insights into treating conditions linked with aberrant RNA methylation and gene expression.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.